Literature DB >> 19464164

Towards rational axillary treatment in relation to neoadjuvant therapy in breast cancer.

M E Straver1, E J Th Rutgers, N S Russell, H S A Oldenburg, S Rodenhuis, J Wesseling, A Vincent, M T F D Vrancken Peeters.   

Abstract

AIMS: The purpose of this study is to analyse nodal staging and axillary response in breast cancer patients treated with neoadjuvant chemotherapy (NAC) to explore venues to safely spare patients axillary clearance whenever it could be avoided.
METHODS: In 327 patients we determined the nodal status before NAC by ultrasound-guided cytology and if indicated by sentinel node biopsy (SNB). In patients with proven metastasis we analysed the axillary response after NAC.
RESULTS: Before NAC, the ultrasound-guided cytology was positive in 252 patients. In the remaining 75 patients SNB was performed prior to NAC. The SNB was negative in 53 patients, thus in these patients axillary clearance could be avoided. All 274 patients with proven axillary metastases at diagnosis underwent axillary clearance after NAC. Twenty percent of the cytology-positive patients (50/252) had an axillary pathological complete remission (pCR) and 68% of the SNB-positive patients (15/22) had no lymph node (LN) metastasis after NAC. Subgroups with a high axillary pCR rate were patients with triple-negative tumours (57%) and human epidermal growth-factor receptor 2 (HER2)-positive tumours (68%) who had a pCR of the primary tumour.
CONCLUSIONS: Twenty percent of the patients with proven metastasis by cytology prior to NAC have an axillary pCR. The axillary pCR rate is very high in certain subgroups. Identification of these patients, could result in more axilla-conserving therapies.

Entities:  

Mesh:

Year:  2009        PMID: 19464164     DOI: 10.1016/j.ejca.2009.04.029

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  17 in total

Review 1.  The need for axillary dissection in patients with positive axillary sentinel lymph nodes.

Authors:  Randal L Croshaw; Kathleen M Erb; Hilary M Shapiro-Wright; Thomas B Julian
Journal:  Curr Oncol Rep       Date:  2011-02       Impact factor: 5.075

2.  Present and future of sentinel lymph node biopsy in breast cancer staging.

Authors:  A Piñero
Journal:  Clin Transl Oncol       Date:  2010-07       Impact factor: 3.405

3.  Outcomes of Sentinel Node Biopsy for Women with Breast Cancer After Neoadjuvant Therapy: Systematic Review and Meta-Analysis of Real-World Data.

Authors:  Shi-Qian Lin; Nguyen-Phong Vo; Yu-Chun Yen; Ka-Wai Tam
Journal:  Ann Surg Oncol       Date:  2022-01-11       Impact factor: 5.344

4.  Neo-Adjuvant Chemotherapy in Luminal, Node Positive Breast Cancer: Characteristics, Treatment and Oncological Outcomes: A Single Center's Experience.

Authors:  Erika Barbieri; Damiano Gentile; Alberto Bottini; Andrea Sagona; Wolfgang Gatzemeier; Agnese Losurdo; Bethania Fernandes; Corrado Tinterri
Journal:  Eur J Breast Health       Date:  2021-10-04

5.  Lymph node effective vascular permeability and chemotherapy uptake.

Authors:  Eelco F J Meijer; Cedric Blatter; Ivy X Chen; Echoe Bouta; Dennis Jones; Ethel R Pereira; Keehoon Jung; Benjamin J Vakoc; James W Baish; Timothy P Padera
Journal:  Microcirculation       Date:  2017-08       Impact factor: 2.628

6.  Feasibility of FDG PET/CT to monitor the response of axillary lymph node metastases to neoadjuvant chemotherapy in breast cancer patients.

Authors:  Marieke E Straver; Tjeerd S Aukema; Renato A Valdes Olmos; Emiel J T Rutgers; Kenneth G A Gilhuijs; Margaret E Schot; Wouter V Vogel; Marie-Jeanne T F D Vrancken Peeters
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-02-04       Impact factor: 9.236

Review 7.  Sentinel lymph nodes for breast carcinoma: an update on current practice.

Authors:  Aoife Maguire; Edi Brogi
Journal:  Histopathology       Date:  2016-01       Impact factor: 5.087

8.  Sentinel lymph node biopsy after neoadjuvant chemotherapy predicts pathological axillary lymph node status in breast cancer patients with clinically positive axillary lymph nodes at presentation.

Authors:  Hiroyuki Takei; Takashi Yoshida; Masafumi Kurosumi; Kenichi Inoue; Hiroshi Matsumoto; Yuji Hayashi; Toru Higuchi; Sayaka Uchida; Jun Ninomiya; Kazuyuki Kubo; Hanako Oba; Shigenori Nagai; Toshio Tabei
Journal:  Int J Clin Oncol       Date:  2012-05-16       Impact factor: 3.402

9.  Sentinel lymph node biopsy alone after neoadjuvant chemotherapy in patients with initial cytology-proven axillary node metastasis.

Authors:  Ji Young Kim; Min Kuk Kim; Jeong Eon Lee; Yongsik Jung; Soo Youn Bae; Se Kyung Lee; Won Ho Kil; Seok Won Kim; Ku Sang Kim; Seok Jin Nam; Sehwan Han
Journal:  J Breast Cancer       Date:  2015-03-27       Impact factor: 3.588

10.  Improved Model for Predicting Axillary Response to Neoadjuvant Chemotherapy in Patients with Clinically Node-Positive Breast Cancer.

Authors:  Hyung Suk Kim; Man Sik Shin; Chang Jong Kim; Sun Hyung Yoo; Tae Kyung Yoo; Yong Hwa Eom; Byung Joo Chae; Byung Joo Song
Journal:  J Breast Cancer       Date:  2017-12-19       Impact factor: 3.588

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.